StockWatch
·

Supriya Lifescience Ltd Q1 FY27 Results

SUPRIYAQ1 FY27 Results
Filing
Result:Weak· Market: DownMargin squeezeCost led

Outlook: Cautiously Optimistic · Guidance: Maintained

MetricValueQ4 FY26Q1 FY26
Revenue189.75 Cr31.4%30.8%
Total Income192.40 Cr31.3%30.2%
Expenditure151.60 Cr19.3%51.1%
PBT40.79 Cr55.7%14.0%
Net Profit24.04 Cr67.6%30.9%
OPM25.01%10.29pp10.63pp
NPM12.50%14.01pp11.05pp
EPS2.9967.6%30.8%
View full financials

Revenue grew a healthy 30.8% YoY but adjusted PAT fell 30.9% as OPM contracted ~1063bps (35.6%→25.0%) on costs outpacing sales, a clear quality miss for pharma despite topline growth.

SUPRIYA LIFESCIENCE · Q1 FY-2027 · THE VERDICT

Revenue beat, margins stumble—execution risk emerges

Supriya reported 31% YoY revenue growth but EBITDA margins compressed to 25% against guided 33–35%. Management blamed temporary water and power shocks totalling ₹10.5 Cr—but even excluding these, a 600–700 bps residual gap points to structural pressure.

18 Aug 2026 · 6 min read
Revenue

₹189.7 Cr

+31% YoY

EBITDA

₹47 Cr

-8.1% YoY; 25% margin

PAT

₹24 Cr

-31% YoY; 12.5% margin

Guidance (margin)

33–35%

Delivered: 25% (−800 bps)

The quarter landed with a paradox: Supriya's top line accelerated 31% YoY to ₹189.7 Cr, outpacing its 20% guidance baseline, yet profit fell 31% YoY to ₹24 Cr. The culprit is margin compression at scale. EBITDA margin landed at 25%, an 800 basis-point miss to the guided 33–35% range. Management pinned ₹10.5 Cr of this to external shocks—water scarcity at Lote and Maharashtra's solar subsidy policy change. But even after accounting for these headwinds, a 600–700 bps gap remains unexplained, signalling structural pressure beneath the growth story.

Margin miss: what holds up, what doesn't

Management claims vs. delivered reality

EBITDA margins impacted by temporary water and power cost shocks totalling ₹10.5 Cr

Overstated

EBITDA ₹47 Cr on ₹189.7 Cr revenue = 24.7% margin. Even with ₹10.5 Cr benefit, margin reaches ~26%, still 700 bps short of 33–35% range

31% YoY revenue growth reflects strong demand

Supported

Revenue ₹189.7 Cr YoY +30.8%, corroborated. But QoQ −31.4% shows severe Q1 dip (water deferral of ₹35 Cr cited)

Excluding one-offs, margins would remain within guided range

Contradicted

Even excluding ₹10.5 Cr external impact, residual margin ~26%, still 700 bps below guidance. New product ramps, CDMO strategy, and Ambernath depreciation (14–15 Cr annualized) driving structural compression

PAT margin at 12.7%

Supported

Delivered PAT ₹24 Cr / revenue ₹189.7 Cr = 12.6% margin

Water deferment of ₹35 Cr will be recovered in coming quarters

Partial

Demand confirmed intact by mgmt; deferral was timing, not loss. Recovery claim plausible but not yet proven

The core issue is earnings quality. PAT fell 31% YoY despite revenue rising 31%—operating leverage has inverted. Ambernath's startup depreciation (14–15 Cr annualized) is one factor. But the deeper pressure is mix: new product launches (anesthetics, contrast media) and the CDMO strategy both start at lower margins as they scale. Management's own commentary acknowledges margins will stay at 33–35% 'for the next 3–4 years' due to CDMO-driven lower initial margins. That is not temporary; that is structural, and it was not front-and-centre in prior guidance.

What changed on this call

Key updates that shift the trajectory
  • Q2 maintenance shutdown cancelled → phased debottlenecking instead

  • Ambernath two anesthetic products launched commercially; EU audit confirmed for November 2026

  • Margin guidance narrowed to 32–35% (from 33–35%)—subtle acknowledgment of floor risk

  • Inventory at ₹230–240 Cr (4.2x monthly revenue); phased liquidation planned over 3–4 quarters

  • Patalganga Phase-1 ground broken; 2.5-year ramp to 40% operational capacity (API blocks, advanced intermediates)

Street view: valuation, flows, and sentiment

The stock fell 2.69% on day 1 post-result, signalling the margin miss was not priced in. Now at ₹803.4, it sits 25.95% below its all-time high of ₹1,085 and trades below both its 20-day and 50-day moving averages (₹853.31 and ₹891.3, respectively), though above the 200-day SMA of ₹754.95. RSI at 39.6 suggests neutral footing, and volume is increasing—a mix of de-risking and potential accumulation. FII ownership ticked up 103 basis points QoQ to 6.19% (from 5.16% in Q4 FY26), suggesting foreign money is buying into the drawdown; DII flat to slightly negative. Promoter holding steady at 68.3%. The tape is saying: the margin miss is real, but the long-term story (CDMO, Patalganga, product launches) retains credibility.

Bull-bear ledger
  • 31% YoY revenue growth outpacing 20% baseline; FY27 ₹1,000 Cr target remains feasible

  • Backward-integrated 72% of revenue (API + advanced intermediate); defensive moat vs. pure-API peers

  • Ambernath CMO/CDMO facility commercially live; EU audit November 2026 unlocks formulation ramps

  • FII inflows (+103 bps QoQ) suggest institutional confidence in long-term story

  • EBITDA margin compressed to 25% vs. 33–35% guided (−800 bps); residual gap 600–700 bps unexplained

  • PAT fell 31% YoY on 31% revenue growth—operating leverage inverted; Ambernath depreciation drag (14–15 Cr annualized)

  • Inventory ₹240 Cr (4.2x monthly revenue); phased liquidation over 3–4 quarters = working capital strain

  • Margin recovery to 33–35% is claimed but not yet proven; guidance narrowed to 32–35%

  • Customs compliance lapse (narcotics shipment, employee in judicial custody); regulatory cost rising

  • CDMO strategy caps margins at 33–35% for next 3–4 years per mgmt commentary—structural, not cyclical ceiling

Risks, ranked by how much they should concern a holder

Key risks in order of severity and impact on returns

Margin recovery unproven; structural compression vs. cyclical

High

Even excluding ₹10.5 Cr external shocks, margin gap is 600–700 bps. Product mix (new launches at lower ramp margins), CDMO strategy (lower-margin innovator deals), and Ambernath startup depreciation are structural, not temporary. If margins do not recover to 33–35% by H2 FY27, street revisions will be steep.

Inventory liquidation over 3–4 quarters = working capital drag + potential for discounting

High

₹240 Cr inventory (4.2x monthly revenue) was built for a cancelled Q2 maintenance shutdown. Planned phased liquidation will tie up cash, constrain product mix flexibility, and may require discounts to accelerate offtake—eroding realized margins further.

Water scarcity recurrence; Lote facility depends on Koyna River monsoon variability

Medium

Q1 ₹35 Cr revenue deferral due to delayed monsoon onset. Water recycling project is early-stage, not yet proven. Lote historically high-rainfall, but monsoon variability is structural to the region. Recurrence would again defer revenue and stress margins.

Power/fuel cost inflation; Maharashtra solar subsidy policy change is structural

Medium

Q1 ₹8 Cr EBITDA impact from solar subsidy policy change. Backpay (₹4.5–5 Cr) is one-time, but forward increases are structural. Mgmt claims cost pass-through to customers on PO basis—but not guaranteed in competitive markets. Margin floor may stay depressed.

Customs/narcotics compliance lapse; precedent risk on export approvals

Medium

One psychotropic (narcotic) shipment lapsed due to human error (logistics GM in judicial custody). Matter sub judice. If CBN tightens precedent on export compliance, broader psychotropic shipment approvals could face delays or scrutiny—adding regulatory cost.

Patalganga Phase-1 capex (₹200 Cr over 2.5 years) execution risk; gate items (MIDC approval, GMP audits) may slip

Medium

Capex is essential to unlock API capacity (Lote saturation) and CDMO upside. But 2.5-year ramp to 40% operational completion is aggressive. Regulatory approvals and GMP audits are gate items; delays would compress medium-term growth.

What to watch next

Four concrete catalysts that resolve the debate
  • 1 · Q2 EBITDA margin delivery (due in ~4–5 weeks post-quarter-end)

    This is the pivot. If margins recover to 28–30% or higher as water/power normalize, the 'temporary shock' thesis holds. If they stay at 25–26%, structural pressure is real and upgrades stall. No need for full 33–35% yet, but the trend direction (recovery vs. continued compression) decides credibility.

  • 2 · Inventory liquidation pace (watch cumulative reduction each quarter)

    Mgmt committed to ₹240 Cr liquidation over 3–4 quarters. If Q2 shows less than ₹60 Cr reduction (normal pace), working capital risk is real and cash flow will stay tight. If ₹80+ Cr, mgmt is aggressive on de-stocking and confidence is rising.

  • 3 · Ambernath EU audit outcome (November 2026)

    CEP (anesthetic API) approval is expected post-audit. Clearance unlocks finished-formulation ramps with European customers, a structural margin upside beyond CMO/CDMO. Delay or findings would push upside into FY28 or later.

  • 4 · CMO/CDMO term sheet announcement (expected Q2 FY27)

    Mgmt flagged a major anesthetic CMO deal close pending in Q2. Scale, margin structure, and customer names will clarify CDMO upside and validate the strategy's return profile.

Supriya Lifescience is not in crisis, but it is in a fork. The company has proven 31% YoY revenue growth and built rare backward-integrated + CDMO capabilities in regulated pharma API space—real moats. But it is also managing down expectations on margins (33–35% to 32–35%), dealing with working capital strain (inventory at 4.2x monthly revenue), and facing structural headwinds (new products ramping at lower initial margins, CDMO strategy capping returns, Ambernath startup depreciation drag). Management's claim that Q1 margin miss was 'largely temporary' does not square with the numbers; even adjusting for externals, a 600–700 bps residual gap points to mix and execution friction.

The honest read: execution risk is real in the near term; the long-term story (CDMO, Patalganga, innovator partnerships) retains credibility if executed. This is not a 'best of breed pharma API' story anymore—it's a 'restructuring into CDMO with margin discipline' story. The debate resolves in Q2–Q3 when margin recovery is either proven or further missed. Until then, hold rather than buy. The single number to track from here is Q2 EBITDA margin. Above 28% and the quarter was an anomaly; below 27% and structural pressure is the narrative.

Informational and educational content only. Not investment advice.